Drugs /

hlx-07

Back to Drugs List

Overview

NCI Definition [1]:
A glycoengineered humanized version of the monoclonal antibody of cetuximab, with potential antineoplastic activity. Upon intravenous administration, pimurutamab selectively targets and binds to the extracellular domain of the epidermal growth factor receptor (EGFR), thereby preventing the activation and subsequent dimerization of the receptor. This may prevent EGFR-mediated signaling and inhibit EGFR-dependent tumor cell proliferation. In addition, the glyco-optimization promotes antibody-dependent cell-mediated cytotoxicity (ADCC). EGFR, a member of the epidermal growth factor family of extracellular protein ligands, may be overexpressed on the cell surfaces of certain tumor types.

Clinical Trials

View Clinical Trials for hlx-07

Hlx-07 has been investigated in 2 clinical trials, of which 1 is open and 1 is closed. Of the trials investigating hlx-07, 1 is phase 1 (0 open) and 1 is phase 2 (1 open).

PD-L1 Expression (CPS >= 1) is the most frequent biomarker inclusion criterion for hlx-07 clinical trials.

Head and neck squamous cell carcinoma is the most common disease being investigated in hlx-07 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Hlx-07
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Hlx-07
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating hlx-07 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
pimurutamab, hlx07, hlx 07, cetuximab biobetter hlx07, anti-egfr monoclonal antibody hlx-07
Drug Target(s) [2]:
EGFR
NCIT ID [1]:
C163981

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.